SAGE-ONF
20.7.2022 02:02:07 CEST | Business Wire | Press release
Sage-ONF, a synthetic leather supplier boasting 29 years of experience in design, development, manufacturing and sales, launches serial production of Silicone Synthetic leather. The Sage-ONF plant has begun manufacturing the Silicone Synthetic leather in Shanghai, China.
As consumers continue to demand greater sustainability commitments, this new venture extends Sage-ONF’s heritage of sustainability by delivering Silicone Synthetic leather as an innovative petroleum-free, non-carbon-based product solution for today’s mobility interiors. With a steadfast conviction to continuous innovation and earth-friendly business practices, this new material avoids DMF and plasticizer usage.
“Bringing together our core competencies as Sage-ONF, we bridge the gap between consumer expectations and industry capabilities to provide alternatives that are both environmentally friendly and bolster animal welfare around the globe,” said Robbie Lv, General Manager of Sage-ONF.
Sage and ONF bring 74 years in the automotive interiors business and a deep understanding of cultural trends and design preferences to deliver unparalleled luxury and a soft hand feel that consumers demand for interior mobility needs. Beyond the touch, consumers can have confidence in their interior’s longevity and cleanability—simply wipe stains with a damp cloth to remove them.
However, experience proves that interiors must be tough enough to tackle mile after mile with a super resilient resistance to extreme temperatures . Using UV, hydrolysis, cold crack and flame tests, Sage-ONF ensures long-lasting interiors that enhance the consumer mobility experience. While many claim superiorities in luxury or in sustainability, Sage-ONF exceeds expectations in both realms by using non-solvent and plasticizer-free techniques to create an opulent silicone with ultra-low VOCs.
“By keeping our product, process and mission as our guide, we are pleased to create a silicone synthetic leather that meets the demanding needs of the mobility interior without leather’s known fragility, extra weight, environmental impact and short lifespan,” said Mark Brezenski, Vice President – Asia at Sage, an Asahi Kasei company. “Sage-ONF is proud to deliver interior materials and solutions of tomorrow to OEMs and consumers, today.”
About Sage Automotive Interiors
Sage Automotive Interiors (www.sageautomotiveinteriors.com ) is one of the world’s leading providers of automotive interior materials—seating, door panel surfaces and headliners—to automotive Original Equipment Manufacturers (OEMs). Global offices and manufacturing locations include the U.S., South America, EMEA and Asia. Sage’s core strengths are consumer research, sustainability and innovative problem solving for the OEM. Sage’s vision is to continually lead the market in design, engineering and technical capability, supported by world-class manufacturing. Sage Automotive Interiors is an Asahi Kasei company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220715005491/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom